BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16333770)

  • 1. Infection and rejection in liver transplant patients: a 10-year Swiss single-centre experience.
    Garbino J; Romand JA; Pittet D; Giostra E; Mentha G; Suter P
    Swiss Med Wkly; 2005 Oct; 135(39-40):587-93. PubMed ID: 16333770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Infectious complications of heart transplantation. A prospective study for the first 6 years of a transplantation program].
    Bernabeu-Wittel M; Cañas García-Otero E; Herrero Romero M; Ordóñez Fernández A; Martínez Martínez A; Pérez Bernal J; Cisneros Herreros JM
    Rev Clin Esp; 1999 Aug; 199(8):489-95. PubMed ID: 10522428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infection in heart transplant recipients: seven years' experience at the National Taiwan University Hospital.
    Ko WJ; Chien NC; Chou NK; Wang SS; Chu SH; Chang SC
    Transplant Proc; 2000 Nov; 32(7):2392-5. PubMed ID: 11120213
    [No Abstract]   [Full Text] [Related]  

  • 4. Infectious complications associated with renal transplantation: an analysis of risk factors.
    Ahern MJ; Comite H; Andriole VT
    Yale J Biol Med; 1978; 51(5):513-25. PubMed ID: 373266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single centre experience.
    Trofe J; Stratta RJ; Egidi MF; Lo A; Gaber LW; Shokouh-Amiri MH; Grewal HP; Honaker M; Hardinger K; Alloway RR; Gaber AO
    Clin Transplant; 2002; 16 Suppl 7():34-44. PubMed ID: 12372042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A clinicopathologic study on complications of orthotopic liver transplantation in 54 patients with chronic hepatitis B virus infection].
    Pei F; Zheng J; Du J; Zhong HH; Yang JP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):408-14. PubMed ID: 18677390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early infection in liver transplant recipients: incidence, severity, risk factors and antibiotic sensitivity of bacterial isolates].
    Losada I; Cuervas-Mons V; Millán I; Dámaso D
    Enferm Infecc Microbiol Clin; 2002 Nov; 20(9):422-30. PubMed ID: 12425875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients.
    Guaraldi G; Cocchi S; Codeluppi M; Di Benedetto F; De Ruvo N; Masetti M; Venturelli C; Pecorari M; Pinna AD; Esposito R
    Transplantation; 2005 Dec; 80(12):1742-8. PubMed ID: 16378070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypogammaglobulinemia and risk of severe infection in kidney transplant recipients.
    Augusto JF; Garnier AS; Demiselle J; Langs V; Picquet J; Legall R; Sargentini C; Culty T; Poli C; Ammi M; Ducancelle A; Chevailler A; Duveau A; Subra JF; Sayegh J
    Transpl Infect Dis; 2016 Oct; 18(5):741-751. PubMed ID: 27509578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon.
    Jain A; Demetris AJ; Manez R; Tsamanadas AC; Van Thiel D; Rakela J; Starzl TE; Fung JJ
    Liver Transpl Surg; 1998 May; 4(3):197-203. PubMed ID: 9563957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study.
    Moreno A; Cervera C; Fortún J; Blanes M; Montejo E; Abradelo M; Len O; Rafecas A; Martín-Davila P; Torre-Cisneros J; Salcedo M; Cordero E; Lozano R; Pérez I; Rimola A; Miró JM;
    Liver Transpl; 2012 Jan; 18(1):70-81. PubMed ID: 21898772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study.
    Vu DL; Dayer JA; Masouridi-Levrat S; Combescure C; Boely E; Khanna N; Mueller NJ; Kleber M; Medinger M; Halter J; Passweg J; Müller AM; Schanz U; Chalandon Y; Neofytos D; van Delden C; Kaiser L;
    Transpl Infect Dis; 2020 Aug; 22(4):e13289. PubMed ID: 32277837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Cao S; Cox KL; Berquist W; Hayashi M; Concepcion W; Hammes GB; Ojogho OK; So SK; Frerker M; Castillo RO; Monge H; Esquivel CO
    Pediatr Transplant; 1999 Feb; 3(1):22-6. PubMed ID: 10359027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive care unit outcomes following orthotopic liver transplantation: single-center experience and review of the literature.
    Damaskos C; Kaskantamis A; Garmpis N; Dimitroulis D; Mantas D; Garmpi A; Sakellariou S; Angelou A; Syllaios A; Kostakis A; Lampadariou E; Floros I; Revenas K; Antoniou EA
    G Chir; 2019; 40(6):463-480. PubMed ID: 32007108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology, risk factors and impact on long-term pancreatic function of infection following pancreas-kidney transplantation.
    Herrero-Martínez JM; Lumbreras C; Manrique A; San-Juan R; García-Reyne A; López-Medrano F; Lizasoain M; de Dios B; Andrés A; Jiménez C; Gutiérrez E; Moreno E; Aguado JM
    Clin Microbiol Infect; 2013 Dec; 19(12):1132-9. PubMed ID: 23480521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of donor and recipient gender on the outcome of liver transplantation.
    Brooks BK; Levy MF; Jennings LW; Abbasoglu O; Vodapally M; Goldstein RM; Husberg BS; Gonwa TA; Klintmalm GB
    Transplantation; 1996 Dec; 62(12):1784-7. PubMed ID: 8990363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of immunosuppressive therapy based on a multiparametric mixed lymphocyte reaction assay reduces infectious complications and mortality in living donor liver transplant recipients.
    Tanaka Y; Tashiro H; Onoe T; Ide K; Ishiyama K; Ohdan H
    Transplant Proc; 2012 Mar; 44(2):555-9. PubMed ID: 22410068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins.
    Farges O; Saliba F; Farhamant H; Samuel D; Bismuth A; Reynes M; Bismuth H
    Hepatology; 1996 Feb; 23(2):240-8. PubMed ID: 8591847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.